OVID-۱۹ vaccination in patients with rheumatic diseases: A crosssectional study in Iran

The severe acute respiratory syndrome coronavirus ۲ (SARS CoV۲), also known as coronavirus disease ۲۰۱۹ (COVID-۱۹), originated in Wuhan, China, and has since become an ongoing pandemic. COVID-۱۹ vaccination has been underway since December ۲۰۲۰. The most common vaccination side effects are pain at the injection site, fever, myalgia, and malaise. The study aimed to investigate any potential complications of COVID-۱۹ vaccination in rheumatic patients. This cross-sectional study was conducted in KUMS[۱]associated rheumatology clinics to identify patients with rheumatic diseases who have received COVID-۱۹ vaccines. The following data were obtained from participants: age, sex, type of vaccine, type of rheumatic disease, medications, side effects, and complications after vaccine injection. Participants were divided into two groups: patients who developed complications and those who did not after vaccine injection. The variables mentioned above were compared between our groups. We identified ۲۹۷ patients with rheumatic diseases (mean age = ۴۹.۱۷ ± ۱۳.۷۹, ۸۱.۵% female) who received at least one dose of the COVID-۱۹ vaccine. Among these, ۱۳۱ (۴۴.۶۶%) reported at least one type of complication following a vaccine injection. The most common side effects were myalgia, fever and chills, headache, injection site pain, and malaise, which were self-limited. Younger patients developed more complications. In contrast, patients taking more than ۵mg of prednisolone on a daily basis had fewer complications. Most vaccine complications in rheumatic patients are self-limiting and similar to healthy individuals. More complications are associated with being younger. Using more than ۵mg of prednisolone daily could be a preventive measure.

کلیدواژه ها:

rheumatic diseases ، COVID-۱۹ ، Sars cov۲ ، Vaccine ، Side Effects